Navigation Links
Fate Therapeutics Strengthens Its iPSC Platform
Date:11/16/2011

Methods 6, 805 - 808 (2009)), and that Thiazovivin promotes the survival of hESCs after single-cell dissociation (Xu, Y., et al, PNAS 107(18): 8129-8134).  Thiazovivin is believed to be a critical factor in maintaining the stem cell niche during conditions that might otherwise be detrimental to cell viability.

About Fate Therapeutics, Inc.

Fate Therapeutics, Inc. interrogates stem cell biology to develop breakthrough therapeutics based on modulating cell fate and to enable a new drug discovery paradigm that includes proprietary induced-pluripotent stem (iPS) cell technology. The company's first therapeutic candidate is in clinical trials in hematopoietic reconstitution. Fate Therapeutics is a private company headquartered in San Diego, CA with a subsidiary in Ottawa, Canada. For more information, please visit www.fatetherapeutics.com.

About The Scripps Research Institute

The Scripps Research Institute is one of the world's largest independent, non-profit biomedical research organizations. Scripps Research is internationally recognized for its discoveries in immunology, molecular and cellular biology, chemistry, neuroscience, and vaccine development, as well as for its insights into autoimmune, cardiovascular, and infectious disease. Headquartered in La Jolla, California, the institute also includes a campus in Jupiter, Florida, where scientists focus on drug discovery and technology development in addition to basic biomedical science. Scripps Research currently employs about 3,000 scientists, staff, postdoctoral fellows, and graduate students on its two campuses. The institute's graduate program, which awards Ph.D. degrees in biology and chemistry, is ranked among the top ten such programs in the nation. For more information, see www.scripps.edu.

Fate Therapeutics, Inc.
Scott Wolchko
Chief Financial Officer
+1-858-875
'/>"/>

SOURCE Fate Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
4. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
5. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
6. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
7. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
8. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
9. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
10. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
11. Arno Therapeutics Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2, 2015 Research and Markets ... of Jain PharmaBiotech,s new report "Nanobiotechnology ... offering. An increasing use ... industries is anticipated. Nanotechnology will be applied ... from formulations for optimal delivery to diagnostic ...
(Date:9/2/2015)... Research and Markets ... Jain PharmaBiotech,s new report "Biochips and Microarrays ... offering. This report is an analysis ... The report starts with a description of technologies ... include array comparative genomic hybridization (CGH), copy number ...
(Date:9/2/2015)... 02, 2015 Research and ... Jain PharmaBiotech,s new report "Gene Therapy - Technologies, ... The markets for gene therapy are difficult to estimate ... and it is marketed in China ... the years 2014-2024. The estimates are based on epidemiology ...
(Date:9/2/2015)... ... 02, 2015 , ... Drug companies increasingly are adopting a ... reveals in its new report that the U.S. will generate the greatest demand ... the most market demand. , BCC Research examines plant-derived drugs in its ...
Breaking Biology Technology:Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3
... /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: ... focused on endocrine therapy and oncology, today announced ... its targeted cytotoxic peptide conjugate compound, AEZS-108 (formerly ... during yesterday,s poster session at the American Society ...
... ... of work that has made a lasting impact on both agriculture and weed science around the ... exploring new control techniques to benefit farmers. Thousands of students have followed in his footsteps and ... ...
... Time TodayBOTHELL, WA, and VANCOUVER, May 30 /PRNewswire-FirstCall/ - ... announced the final results of a Randomized Phase 2 ... Society of Clinical Oncology (ASCO) Annual Meeting. Analyses indicated ... combination with docetaxel compared to docetaxel alone - the ...
Cached Biology Technology:AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting 2AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting 3Blazing Trails: Dr. Ellery Knake Remembered for His Contributions to Weed Science 2Blazing Trails: Dr. Ellery Knake Remembered for His Contributions to Weed Science 3Blazing Trails: Dr. Ellery Knake Remembered for His Contributions to Weed Science 4OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer 2OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer 3OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer 4OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer 5OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer 6OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer 7OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer 8
(Date:9/1/2015)... Calif. , Sept. 1, 2015  Automation ... travelers during airport passenger screening. This is the ... passenger screening process will become unintrusive. An assortment ... based on voluntary background investigations will transform the ... Frost & Sullivan, Global Airport Passenger Screening ...
(Date:8/31/2015)... Aug. 31, 2015 Research and Markets ( ... "Saudi Arabia Biomedical Sensors Market - Growth, Trends & ... The Saudi Arabia Biomedical Sensors market is estimated ... 3.64% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:8/26/2015)... The report "Multi-Factor Authentication (MFA) Market ... (Travel & Immigration, Government, Banking, Defense, Commercial Security, Consumer ... published by MarketsandMarkets, Multi-Factor Authentication Market is expected to ... CAGR of 17.7% between 2015 and 2020. ... spread through 169 P ages and ...
Breaking Biology News(10 mins):The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 2The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 3The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 4Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5
... investigated the cycling of molybdenum (Mo) in ancient oceans ... in sedimentary rocks from Grand Canyon that formed in ... Dahl, who did this research in collaboration with researchers ... Center of Earth Evolution in Denmark (NordCEE). ...
... Student Learning Capabilities , (#1112887, Tuesday, October 25, ... during simulation education may have negative effects on learning. ... a mannequin during a simulated medical exercise involving final ... "death" of the "patient" during a procedure. Students (n=116) ...
... School for Science and Technology is the first post-secondary school ... Visualized Experiments . Though JoVE , the first ... has video articles showing basic experimental procedures, the majority of ... schools -- not the level of research one would usually ...
Cached Biology News:Poisonous oceans delayed animal evolution 2CHEST 2011: Embargoed studies highlight new simulation education research 2
Fujifilm BAS-1800II provides the ideal configuration for a low-cost imager that requires only a small amount of space in the laboratory. The small imager for accurate high-throughput screening...
When added to StemSep T Cell Enrichment cocktail, human TCRab TAC is designed to deplete human TCRab from samples to isolate gd T cells....
... The Aquarius 384 is a ... Aquarius 384-well head is a unique ... washing using the included wash system. ... 250 microplate stacker system. Will ...
... The Eclipse C1 Plus is a ... highest-quality digital imaging with an ultra-compact and ... of the C1 Plusboost optical performance to ... acquisition.The system alsoincludes support for X and ...
Biology Products: